• AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study pharmaceutical-technology
    March 10, 2021
    AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.
PharmaSources Customer Service